Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 3/2015

01-03-2015 | Medical Oncology

Clinicopathological Significance of CXCR4 Expression in Renal Cell Carcinoma: A Meta-Analysis

Authors: Bo Tang, MD, Fang Tang, MD, Yang Li, BSc, Shengguang Yuan, MD, Bo Li, MSc, Zhenran Wang, MD, Songqing He, MD

Published in: Annals of Surgical Oncology | Issue 3/2015

Login to get access

Abstract

Background

Emerging evidence indicates that C-X-C chemokine receptor type 4 (CXCR4) is a candidate oncogene in several types of human tumors including renal cell carcinoma (RCC). We conducted a meta-analysis to quantitatively evaluate the association of CXCR4 expression with the incidence of RCC and clinicopathological characteristics.

Methods

We searched PubMed, Embase, and ISI Web of Knowledge to identify studies written in English. Methodological quality of the studies was also evaluated. Odds ratio and hazard ratio were calculated and summarized.

Results

Final analysis was performed of 994 RCC patients from 11 eligible studies. We observed that CXCR4 expression was significantly higher in RCC than in normal renal tissues. CXCR4 expression was not found to be associated with sex status or clinical staging. However, CXCR4 expression was clearly associated with Fuhrman grading, metastatic status, and overall survival in RCC patients.

Conclusions

The results of this meta-analysis suggest that CXCR4 expression is associated with an increased risk and worsen survival in RCC patients. The aberrant CXCR4 expression plays an important role in the carcinogenesis and metastasis of RCC.
Literature
1.
2.
Custodio S, Joaquim A, Peixoto V, et al. Metastatic renal cell carcinoma: the importance of immunohistochemistry in differential diagnosis. Case Rep Oncol. 2012;5:30–4.PubMedCentralPubMedCrossRef
3.
Eisengart LJ, MacVicar GR, Yang XJ. Predictors of response to targeted therapy in renal cell carcinoma. Arch Pathol Lab Med. 2012;136:490–5.PubMedCrossRef
4.
Moriuchi M, Moriuchi H, Turner W, Fauci AS. Cloning and analysis of the promoter region of CXCR4, a coreceptor for HIV-1 entry. J Immunol. 1997;159:4322–9.PubMed
5.
Caruz A, Samsom M, Alonso JM, et al. Genomic organization and promoter characterization of human CXCR4 gene. FEBS Lett. 1998;426:271–8.PubMedCrossRef
6.
Huang CS, Tang SJ, Chung LY, et al. Galectin-1 upregulates CXCR4 to promote tumor progression and poor outcome in kidney cancer. J Am Soc Nephrol. 2014;25(7):1486–95.PubMedCrossRef
7.
Wang L, Huang T, Chen W, et al. Silencing of CXCR4 by RNA interference inhibits cell growth and metastasis in human renal cancer cells. Oncol Rep. 2012;28:2043–8.PubMed
8.
9.
Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature. 2003;425:307–11.PubMedCrossRef
10.
11.
12.
DerSimonian R. Meta-analysis in the design and monitoring of clinical trials. Stat Med. 1996;15:1237–48; discussion 49–52.
13.
14.
Huang CS, Tang SJ, Chung LY, et al. Galectin-1 Upregulates CXCR4 to Promote Tumor Progression and Poor Outcome in Kidney Cancer. J Am Soc Nephrol. 2014;7:7.
15.
Wang L, Chen W, Gao L, et al. High expression of CXCR4, CXCR7 and SDF-1 predicts poor survival in renal cell carcinoma. World J Surg Oncol. 2012;10:212.PubMedCentralPubMedCrossRef
16.
Li X, Huang Y, Xia J, et al. CXCR4 expression in patients with high-risk locally advanced renal cell carcinoma can independently predict increased risk of disease progression and poor overall survival. Asian Pac J Cancer Prev. 2011;12:3313–8.PubMed
17.
D’Alterio C, Cindolo L, Portella L, et al. Differential role of CD133 and CXCR4 in renal cell carcinoma. Cell Cycle. 2010;9:4492–500.PubMedCrossRef
18.
Zhao FL, Guo W. Expression of stromal derived factor-1 (SDF-1) and chemokine receptor (CXCR4) in bone metastasis of renal carcinoma. Mol Biol Rep. 2011;38:1039–45.PubMedCrossRef
19.
Wang L, Yang B, Yang Q, Qiao S, Wang Y, Sun Y. Strong expression of chemokine receptor CXCR4 by renal cell carcinoma cells correlates with metastasis. Clin Exp Metastasis. 2009;26:1049–54.PubMedCrossRef
20.
21.
Li G, Badin G, Zhao A, et al. Prognostic value of CXCR4 expression in patients with clear cell renal cell carcinoma. Histol Histopathol. 2013;28:1217–22.PubMed
22.
Wehler TC, Graf C, Biesterfeld S, et al. Strong expression of chemokine receptor CXCR4 by renal cell carcinoma correlates with advanced disease. J Oncol. 2008;2008:626340.PubMedCentralPubMedCrossRef
23.
Hao T, Zhou L, Wang X, Xuan Q, Cao Z. Expression of HIF-1 alpha and CXCR4 in renal clear cell cancer. Acta Universitis Medicinalis Anhui 2010;2:168–72.
Metadata
Title
Clinicopathological Significance of CXCR4 Expression in Renal Cell Carcinoma: A Meta-Analysis
Authors
Bo Tang, MD
Fang Tang, MD
Yang Li, BSc
Shengguang Yuan, MD
Bo Li, MSc
Zhenran Wang, MD
Songqing He, MD
Publication date
01-03-2015
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 3/2015
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-4019-5

Other articles of this Issue 3/2015

Annals of Surgical Oncology 3/2015 Go to the issue

Hepatobiliary Tumors

RAS Mutations Predict Radiologic and Pathologic Response in Patients Treated with Chemotherapy Before Resection of Colorectal Liver Metastases

Hepatobiliary Tumors

Is Yttrium-90 Radioembolization a Viable Treatment Option for Unresectable, Chemorefractory Colorectal Cancer Liver Metastases? A Large Single-Center Experience of 302 Patients

Breast Oncology

Global Surgical Oncology Disease Burden: Addressing Disparities Via Global Surgery Initiatives: The University of Michigan International Breast Cancer Registry

Gastrointestinal Oncology

What Factors Are Necessary for the Safe and Feasible Performance of Total Gastrectomy?

Hepatobiliary Tumors

Lymph Node Metastases in Patients Undergoing Surgery for a Gallbladder Cancer. Extension of the Lymph Node Dissection and Prognostic Value of the Lymph Node Ratio

Thoracic Oncology

Impact of Pretreatment Imaging on Survival of Esophagectomy After Induction Therapy for Esophageal Cancer: Who Should be Given the Benefit of the Doubt?